新诊断脑转移瘤立体定向放射外科治疗后新发癫痫的相关因素
单中心回顾性分析2013至2016年305例无癫痫史、因新诊断脑转移瘤接受立体定向放射外科治疗的患者,26例(8.5%)在3个月内新发癫痫。多因素分析显示总照射体积(每增加1 cm³ OR 1.09,95%CI 1.02-1.17,P=.016)和SRS前神经系统症状(OR 3.08,95%CI 1.19-7.99,P=.020)与新发癫痫显著相关。作者认为高总治疗体积和就诊时局灶性神经功能缺损与新发癫痫相关,高危患者可能从咨询或预防性抗癫痫治疗中获益。
要点
- 305例中26例(8.5%)在SRS后3个月内新发癫痫。
- 总照射体积每增加1 cm³,癫痫OR为1.09(95%CI 1.02-1.17,P=.016)。
- SRS前有神经系统症状者癫痫OR为3.08(95%CI 1.19-7.99,P=.020)。
核心结论
- 作者认为较大的总治疗体积和就诊时存在局灶性神经功能缺损与SRS后3个月内新发癫痫相关。
- 作者提出高危患者接受SRS可能从咨询或预防性抗癫痫治疗中获益。
研究设计与样本
- 单中心回顾性研究,纳入2013年至2016年因新诊断脑转移瘤接受SRS的患者305例。
- 收集基线人口学、放射参数和临床病程数据。
主要发现
- 中位年龄64岁(四分位距55-70),基线卡氏功能状态评分中位80(四分位距80-90)。
- 26例(8.5%)在SRS后3个月内新发癫痫。
- 新发癫痫与基线卡氏功能状态评分中位值、既往切除或既往全脑放疗无关联。
- 有无新发癫痫患者间,总照射体积(12.5 vs 3.7 cm³,P<.001)、最大单病灶体积(8.8 vs 2.8 cm³,P=.003)、病灶直径(3.2 vs 2.0 cm,P=.003)和治疗的病灶数(3 vs 1,P=.018)存在显著差异。
- 多因素logistic回归显示总照射体积(每增加1 cm³ OR 1.09,95%CI 1.02-1.17,P=.016)和SRS前神经系统症状(OR 3.08,95%CI 1.19-7.99,P=.020)与SRS后癫痫风险显著相关。
临床怎么用
- 作者认为高总治疗体积和就诊时局灶性神经功能缺损的高危患者接受SRS可能从咨询或预防性抗癫痫治疗中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) is a highly effective therapy for newly diagnosed brain metastases. Prophylactic antiepileptic drugs are no longer routinely used in current SRS practice, owing to a perceived low overall frequency of new-onset seizures and potential side effects of medications. It is nonetheless desirable to prevent unwanted side effects following SRS. Risk factors for new-onset seizures after SRS have not been well established. As such, we aimed to characterize variables associated with increased seizure risk. METHODS AND MATERIALS: Patients treated with SRS for newly diagnosed brain metastases between 2013 and 2016 were retrospectively reviewed at a single institution. Data on baseline demographics, radiation parameters, and clinical courses were collected. RESULTS: The cohort consisted of 305 patients treated with SRS without prior seizure history. Median age and baseline Karnofsky Performance Scale score were 64 years (interquartile range, 55-70) and 80 (interquartile range, 80-90), respectively. Twenty-six (8.5%) patients developed new-onset seizures within 3 months of SRS. There was no association between new-onset seizures and median baseline Karnofsky Performance Scale score, prior resection, or prior whole brain radiation therapy. There were significant differences in the combined total irradiated volume (12.5 vs 3.7 cm3, P < .001), maximum single lesion volume (8.8 vs 2.8 cm3, P = .003), lesion diameter (3.2 vs 2.0 cm, P = .003), and number of lesions treated (3 vs 1, P = .018) between patients with and without new-onset seizures, respectively. On multivariate logistic regression, total irradiated volume (odds ratio, 1.09 for every 1-cm1 increase in total volume; confidence interval, 1.02-1.17; P = .016) and pre-SRS neurologic symptoms (odds ratio, 3.08; 95% confidence interval, 1.19-7.99; P = .020) were both significantly correlated with odds of seizures following SRS. CONCLUSIONS: Our data suggest that larger total treatment volume and the presence of focal neurologic deficits at presentation are associated with new-onset seizures within 3 months of SRS. High-risk patients undergoing SRS may benefit from counseling or prophylactic antiseizure therapy.
引用
- Lerner EC, Srinivasan ES, Broadwater G, et al. Factors Associated With New-Onset Seizures Following Stereotactic Radiosurgery for Newly Diagnosed Brain Metastases. Adv Radiat Oncol. 2022. PMID: 36420187. doi:10.1016/j.adro.2022.101054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。